EP3223794A1 - Stabilized omega-3 ophthalmic compositions - Google Patents

Stabilized omega-3 ophthalmic compositions

Info

Publication number
EP3223794A1
EP3223794A1 EP15805372.8A EP15805372A EP3223794A1 EP 3223794 A1 EP3223794 A1 EP 3223794A1 EP 15805372 A EP15805372 A EP 15805372A EP 3223794 A1 EP3223794 A1 EP 3223794A1
Authority
EP
European Patent Office
Prior art keywords
oil
ophthalmic composition
composition
stearate
poe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP15805372.8A
Other languages
German (de)
French (fr)
Inventor
Anuradha V. Gore
Jaya GIYANANI
Sukhon Likitlersuang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54784036&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP3223794(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of EP3223794A1 publication Critical patent/EP3223794A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/55—Linaceae (Flax family), e.g. Linum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Definitions

  • compositions containing omega-3 oils are useful as artificial tears and as ophthalmic compositions to diagnose, treat, or prevent dry eye syndrome or
  • keratoconjunctivitis in a human or other mammal in need of such diagnosis treatment, or prevention.
  • Omega-3 oils are widely noted in the published literature for their beneficial effects on ocular health, and certain omega-3 fatty acids are known to be significant components of the mammalian eye. See, e.g., Insight, Oct-Dec; 33(4): 20-5 (2008).
  • a majority of omega-3 oil products are formulated as soft or hard gel capsules filled with omega-3 oil compositions which are intended for oral and systemic delivery of the omega-3 oils.
  • omega-3 oils for ocular surface delivery.
  • Emulsions are typically the preferred dosage form for delivery of oily components to the surface of the eye, in which the oil dispersed in the water phase as droplets typically in the sub-micron range by using surfactants and emulsifiers.
  • a major hurdle in development of an ophthalmic product containing the omega-3 oils is the chemical stability of the omega-3 components which are susceptible degradation by oxidation and hydrolysis.
  • U.S. 2007/0265341 teaches the use of vitamin E as an antioxidant, but vitamin E is not effective in preserving omega-3 oils as described herein. Thus, there is a need for stable ophthalmic compositions containing omega-3 oils.
  • antioxidants are selected from butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT), alone or in combination. These compositions may be used, among other things, as artificial tears and as ophthalmic compositions to diagnose, treat, or prevent keratoconjunctivitis or dry eye syndrome in a human or other mammal in need of such diagnosis, treatment, or prevention.
  • BHA butylated hydroxyanisole
  • BHT butylated hydroxytoluene
  • FIG. 1 shows the improved chemical stability of omega-3 oils in emulsions containing BHA and BHT, as compared to emulsions containing omega-3 oil without BHA/BHT.
  • FIG. 2 shows flaxseed oil emulsion formulation stability over time.
  • FIG. 3 shows in vivo tolerability results of omega-3 oil emulsions.
  • antioxidants are selected from butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT), alone or in combination.
  • Butylated hydroxytoluene is also known as butylhydroxytoluene, tert- butylhydroxytoluene, or 2,6-bis(1 ,1-dimethylethyl)-4-methylphenol. Butylated
  • hydroxyanisole is also known as butylhydroxyanisole or terf-butylhydroxyanisole.
  • BHA commonly includes a mixture of 2-terf-butyl-4-hydroxyanisole and 3-terf-butyl-4- hydroxyanisole.
  • BHA, BHT, or combinations thereof exhibit a unique stabilizing effect on omega-3 oils as compared to other known antioxidants.
  • a variety of ophthalmic compositions were evaluated which contained antioxidants with the intent to prevent the degradation of the omega-3 oil components.
  • a common problem with omega-3 oils is their propensity to degrade and become rancid over time.
  • many commonly used antioxidants for oils such as ascorbyl palmitate, alpha tocopherol and Vitamin E acetate did not show beneficial effects in protecting the omega -3 components from degradation. Even more surprisingly, in some cases these antioxidants enhanced the degradation rates of the omega-3 oils. Only BHA and BHT were found to have a stabilizing effect on the omega-3 oils.
  • Emulsion prototypes were designed using a range of excipients including different surfactants, antioxidants and aqueous additives.
  • the physical and chemical stability of these prototype formulations were monitored over 3, 6 and/or 12 months at accelerated and/or long term storage conditions. It was found that emulsions containing BHA and/or BHT were chemically and physically stable for 3, 6 and/or 12 months at accelerated and/or long term storage conditions.
  • Other oil soluble antioxidants such as Vitamin E acetate, ascorbyl palmitate and alpha-tocopherol led to degradation of omega-3 oil along with a change in physical appearance of the emulsions.
  • Water soluble additives such as EDTA, trehalose and pyruvate did not impact stability for the emulsions. Details of these stability studies are provided in the examples herein.
  • compositions provided herein may be used, among other things, as artificial tears and/or as ophthalmic compositions for the treatment of dry eye, or to diagnose, treat, or prevent keratoconjunctivitis or dry eye syndrome in man or other animals.
  • the ophthalmic compositions provided herein may also include one or more therapeutic agents, in addition to one or more omega-3 oils.
  • the ophthalmic compositions provided herein may contain other ingredients suitable for ophthalmic use. These compositions are also referred to as ophthalmically acceptable liquids.
  • An ophthalmically acceptable liquid includes a liquid formulated to be tolerable to a patient for topical ophthalmic use.
  • An ophthalmically acceptable liquid may be a solution or an emulsion.
  • compositions/medicaments may be prepared, for example, by using a physiological saline solution as a major vehicle. Ophthalmic solutions or compositions may be maintained at a comfortable pH with an appropriate buffer system.
  • the formulations may also contain conventional, pharmaceutically acceptable preservatives, stabilizers and surfactants.
  • the ophthalmic composition provided herein includes a buffer.
  • the buffer may vary, and may include any weak conjugate acid-base pair suitable for maintaining a desirable pH range. Examples include, but are not limited to, acetate buffers, citrate buffers, phosphate buffers, borate buffers, or a combination thereof. Acids or bases may be used to adjust the pH of these formulations as needed.
  • the amount of buffer used may vary.
  • the buffer may have a concentration in a range of about 1 nM to about 100 mM.
  • the pH of a buffered solution may be increased by the addition of NaOH or another base, or decreased by the addition of HCI or another acid.
  • the pH of a composition may be about 6.4 to about 7.8; 6.8 to about 7.5; 6.8 to about 7.4; 6.8 to about 7.3; 6.8 to about 7.2; 6.9 to about 7.1 ; or about 6.8; about 6.9; about 7.0; about 7.1 ; about 7.2 or about 7.3.
  • An ophthalmic composition provided herein may include one or more surfactants.
  • the surfactant may vary, and may include any compound that is surface active or can form micelles.
  • a surfactant may be used for assisting in dissolving an excipient or an active agent, dispersing a solid or liquid in a composition, enhancing wetting, modifying drop size, stabilizing an emulsion, or a number of other purposes.
  • Useful surfactants include, but are not limited to, surfactants of the following classes: alcohols; amine oxides; block polymers; carboxylated alcohol or alkylphenol
  • ethoxylates carboxylic acids/fatty acids; ethoxylated alcohols; ethoxylated alkylphenols; ethoxylated aryl phenols; ethoxylated fatty acids; ethoxylated; fatty esters or oils (animal and vegetable); fatty esters; fatty acid methyl ester ethoxylates; glycerol esters; glycol esters; lanolin-based derivatives; lecithin and lecithin derivatives; lignin and lignin derivatives; methyl esters; monoglycerides and derivatives; polyethylene glycols;
  • the surfactant may include polyethylene glycol (15)-hydroxystearate (CAS Number 70142-34-6, available as Solutol HS 15® from BASF), polyoxyethylene-polyoxypropylene block copolymer (CAS No. 9003-1 1 -6, available as Pluronic® F-68 from BASF), polyoxyethylene 40 stearate (POE 40 stearate), polysorbate 80 or polyoxyethylene (80) sorbitan monooleate (CAS No.
  • An ophthalmic composition provided herein may include one or more viscosity modifying agents, including the class of hydrogel polymers.
  • viscosity modifying agents include, but are not limited to, carboxymethyl cellulose (CMC) and salts thereof, cellulose polymers such as hydroxypropyl methyl cellulose (HPMC), alkyl acrylate crosspolymers such as a acrylates/C 10-30 alkyl acrylate crosspolymer (e.g.
  • PemulenTM polyvinylpyrrolidone (PVP), hyaluronic acid (HA) and salts thereof, hydroxyethyl cellulose (HEC), ethyl hydroxyethyl cellulose, hydroxypropyl cellulose, methyl cellulose, dextran 70, gelatin, glycerine, polyethylene glycols, polysorbate 80, propylene glycol, povidone, carbomers, polyvinyl alcohol, alginates, carrageenans, guar gum, karaya gum, agarose gum, locust bean gum, tragacanth gum and xanthan gum.
  • the hydrogel polymer is selected from CMC and its salts, HPMC, PVP, HEC, HA and its salts, and mixtures thereof. In some embodiments, the hydrogel polymer is sodium CMC.
  • the viscosity agent may be a combination of a hydrogel polymer and an alkyl acrylate crosspolymer, such as an acrylates/C 10-30 alkyl acrylate crosspolymer.
  • PemulenTM TR-2 (Lubrizol Corporation, Wickliffe, OH) is a commercially available acrylates/C 10-30 alkyl acrylate crosspolymer.
  • the amount of acrylates/C 10-30 alkyl acrylate crosspolymer is about 0.5% to about 1 .5%; or about 0.8% to about 1 .2%; or about 0.9% to about 1 .1 %; or about 1 .0%.
  • An ophthalmic composition provided herein may include one or more tonicity agents.
  • the tonicity agent may vary, and may include any compound or substance useful for adjusting the tonicity of an ophthalmic liquid. Examples include, but are not limited to, salts, particularly sodium chloride, potassium chloride, magnesium chloride and calcium chloride; polyols and sugars such as glycerin (glycerol), propylene glycol, erythritol, mannitol, sorbitol and trehalose; amino acids such as carnitine (e.g., levocarnitine or L-carnitine) and betaine; or any other suitable ophthalmically acceptable tonicity adjustor.
  • salts particularly sodium chloride, potassium chloride, magnesium chloride and calcium chloride
  • polyols and sugars such as glycerin (glycerol), propylene glycol, erythritol, mannitol, sorbitol and trehalose
  • amino acids such
  • the amount of tonicity agent may vary depending upon whether an isotonic, hypertonic, or hypotonic liquid is desired. In some embodiments, the amount of a tonicity agent such as those listed above may be at least about 0.001 % up to about 1 %, about 2%, or about 5%. In some embodiments, the amount of each tonicity agent is about 0.125%, about 0.25%, about 0.4%, about 0.5%, about 0.6%, about 0.75%, about 1 .0%, about 1 .25%, about 1 .5%, about 1.75%, or about 2.0%
  • the tonicity agents used herein to provide substantially isotonic, or slightly hypotonic, ophthalmically acceptable compositions are 150 to 450 mOsm/kg; 250 to 330 mOsm/kg; 270 to 310 mOsm/kg; or about 240 mOsm/kg.
  • An ophthalmic composition provided herein may include one or more chelating agents.
  • the chelating agent may vary, and may include any compound or substance that is capable of chelating a metal.
  • a useful chelating agent is edetate disodium (EDTA), although other chelating agents may also be used in place or in conjunction with it.
  • preservatives the compositions provided herein do not contain such preservatives.
  • examples of such excluded preservatives include, but are not limited to, cationic preservatives such as quaternary ammonium compounds including benzalkonium chloride, polyquad, and the like; guanidine-based preservatives including PHMB, chlorhexidine, and the like; chlorobutanol; mercury preservatives such as thimerosal, phenylmercuric acetate and phenylmercuric nitrate; and oxidizing preservatives such as stabilized oxychloro complexes (e.g. Purite®).
  • cationic preservatives such as quaternary ammonium compounds including benzalkonium chloride, polyquad, and the like
  • guanidine-based preservatives including PHMB, chlorhexidine, and the like
  • chlorobutanol chlorobutanol
  • mercury preservatives such as thimeros
  • compositions provided herein may be aqueous solutions or emulsions, or some other acceptable liquid form.
  • oils in addition to the omega-3 oils may be used to in the emulsion.
  • suitable oils include, but are not limited to anise oil, castor oil, clove oil, cassia oil, cinnamon oil, almond oil, corn oil, arachis oil, cottonseed oil, safflower oil, maize oil, linseed oil, rapeseed oil, soybean oil, olive oil, caraway oil, rosemary oil, peanut oil, peppermint oil, sunflower oil, eucalyptus oil, sesame oil, and the like.
  • the addition oil is castor oil.
  • omega-3 oils include, but are not limited to, botanical oils such as linseed (flaxseed or linum usitatissimum), chia (chia sage or salvia hispanica), kiwifruit (Chinese gooseberry or actinidia chinensis), perilla (shiso or perilla frutescens), lingonberry (cowberry or vaccinium vitis-idaea), camelina (gold-of-pleasure or camelina sativa), purslane (portulaca or portulaca oleracea) and black raspberry ⁇ rubus occidentalis); and oils from cold water fish such as cod liver oil, salmon oil, anchovy oil and tuna oil.
  • the omega-3 oil is flaxseed oil.
  • Table 1 Exemplary omega-3 acids present in omega-3 oils
  • HTA Hexadecatrienoic acid M 6:3 (n-3) all-cis-7, 10, 13-hexadecatrienoic acid
  • ALA a-Linolenic acid (ALA) M 8:3 (n-3) all-cis-9, 12, 15-octadecatrienoic acid
  • ETE Eicosatrienoic acid
  • Eicosatetraenoic acid 120:4 (n-3) all-cis-8, 1 1 , 14,17-eicosatetraenoic acid
  • DPA Docosapentaenoic acid
  • Tetracosahexaenoic acid (Nisinic acid) ; 24:6 (n-3) all-cis-6,9, 12, 15, 18,21 -tetracosahexaenoic acid
  • compositions provided herein may include, as an "omega-3 oil” one of the omega-3 acids of Table 1 or mixtures thereof, either from synthetic sources or as isolated from a natural oil.
  • Table 2 provides examples of plant seed oils which may be used as source of omega-3 components. One or more of the oils provided in Table 2 may be used as the omega-3 oil source for the emulsion formulations. [0030] Table 2
  • the ophthalmic compositions provided herein comprise one or more omega-3 oils, castor oil, BHT and/or BHA, one or more hydrogels, one or more tonicity agents, one or more surfactants, and an acrylates/C 10- 30 alkyl acrylate crosspolymer, and do not include an antimicrobial preservative.
  • the ophthalmic compositions provided herein comprise flaxseed oil, castor oil, BHT and/or BHA, one or more hydrogels, one or more tonicity agents, one or more surfactants, and an acrylates/C 10-30 alkyl acrylate crosspolymer, and do not include an antimicrobial preservative.
  • an ophthalmic composition comprising flaxseed oil, castor oil, BHT, one or more hydrogels, one or more tonicity agents, one or more surfactants, and an acrylates/C 10-30 alkyl acrylate crosspolymer, and wherein the composition does not include an antimicrobial preservative.
  • an ophthalmic composition comprising flaxseed oil, castor oil, BHA, one or more hydrogels, one or more tonicity agents, one or more surfactants, and an acrylates/C 10-30 alkyl acrylate crosspolymer, and wherein the composition does not include an antimicrobial preservative.
  • an ophthalmic composition comprising flaxseed oil, castor oil, BHT, BHA, one or more hydrogels, one or more tonicity agents, one or more surfactants, and an acrylates/C10-30 alkyl acrylate crosspolymer, and wherein the composition does not include an antimicrobial preservative.
  • an ophthalmic composition comprising flaxseed oil; castor oil; BHT and/or BHA; CMC or a salt thereof; one or more tonicity agents; one or more surfactants; and an acrylates/C 10-30 alkyl acrylate crosspolymer; and wherein the composition does not include an antimicrobial preservative.
  • an ophthalmic composition comprising flaxseed oil; castor oil; BHT and/or BHA; CMC or a salt thereof; one or more tonicity agents selected from carnitine, glycerin, erythritol and trehalose; one or more
  • composition does not include an antimicrobial preservative.
  • an ophthalmic composition comprising flaxseed oil; castor oil; BHT and/or BHA; CMC or a salt thereof; one or more tonicity agents selected from carnitine, glycerin, erythritol and trehalose; one or more
  • surfactants selected from polysorbate 80 and POE 40 stearate; and an acrylates/C 10- 30 alkyl acrylate crosspolymer; and wherein the composition does not include an antimicrobial preservative.
  • an ophthalmic composition comprising flaxseed oil; castor oil; BHT and/or BHA; sodium CMC; one or more tonicity agents selected from carnitine, glycerin, erythritol and trehalose; one or more surfactants selected from polysorbate 80 and POE 40 stearate; and an acrylates/C 10-30 alkyl acrylate crosspolymer; and wherein the composition does not include an antimicrobial preservative.
  • an ophthalmic composition comprising flaxseed oil; castor oil; BHT and/or BHA; sodium CMC; one or more tonicity agents selected from carnitine, glycerin, erythritol and trehalose; polysorbate 80; POE 40 stearate; and an acrylates/C 10-30 alkyl acrylate crosspolymer; and wherein the composition does not include an antimicrobial preservative.
  • an ophthalmic composition comprising flaxseed oil; castor oil; BHT and/or BHA; sodium CMC; carnitine; glycerin; erythritol; trehalose; a buffer; polysorbate 80; POE 40 stearate; and an acrylates/C10-30 alkyl acrylate crosspolymer; and wherein the composition does not include an antimicrobial preservative.
  • an ophthalmic composition comprising flaxseed oil; castor oil; BHT and/or BHA; sodium CMC; carnitine; glycerin; erythritol; trehalose; boric acid; polysorbate 80; POE 40 stearate; and an acrylates/C 10-30 alkyl acrylate crosspolymer; and wherein the composition does not include an antimicrobial preservative.
  • an ophthalmic composition comprising flaxseed oil; castor oil; BHT; sodium CMC; carnitine; glycerin; erythritol; trehalose; boric acid; polysorbate 80; POE 40 stearate; an acrylates/C 10-30 alkyl acrylate crosspolymer; and water; and wherein the composition does not include an antimicrobial preservative.
  • an ophthalmic composition comprising flaxseed oil; castor oil; BHT; BHA; sodium CMC; carnitine; glycerin; erythritol; trehalose; boric acid; polysorbate 80; POE 40 stearate; an acrylates/C 10-30 alkyl acrylate crosspolymer; and water; and wherein the composition does not include an
  • “about” includes a +/- 30% variation from the value provided. In some embodiments, “about” includes a +/- 25% variation from the value provided. In some embodiments, “about” includes a +/- 10% variation from the value provided. In some embodiments, “about” includes a +/- 5% variation from the value provided. In some embodiments, “about” includes a +/- 1 % variation from the value provided.
  • an ophthalmic composition comprising about 0.1 % to about 1 % w/w flaxseed oil; about 0.1 % to about 1 % w/w castor oil; about 0.001 % to about 0.05% w/w BHT; about 0.001 % to about 0.05% w/w BHA; about 0.25% to about 1 % w/w sodium CMC; about 0.1 % to about 0.5% w/w carnitine; about 0.1 % to about 2% w/w glycerin; about 0.1 % to about 0.5% w/w erythritol; about 0.5% to about 3% w/w trehalose; about 0.1 % to about 2% w/w boric acid; about 0.1 % to about 2% w/w polysorbate 80; about 0.1 % to about 2% w/w POE 40 stearate; about 0.1 % to about 1 % w/w
  • an ophthalmic composition comprising about 0.1 % to about 1 % w/w flaxseed oil; about 0.1 % to about 1 % w/w castor oil; about 0.001 % to about 0.05% w/w BHT; about 0.25% to about 1 % w/w sodium CMC; about 0.1 % to about 0.5% w/w carnitine; about 0.1 % to about 2% w/w glycerin; about 0.1 % to about 0.5% w/w erythritol; about 0.5% to about 3% w/w trehalose; about 0.1 % to about 2% w/w boric acid; about 0.1 % to about 2% w/w polysorbate 80; about 0.1 % to about 2% w/w POE 40 stearate; about 0.05% to about 1 % w/w acrylates/C 10-30 alkyl acrylate crosspolymer; and
  • an ophthalmic composition comprising about 0.1 % to about 0.5% w/w flaxseed oil; about 0.1 % to about 0.5% w/w castor oil; about 0.005% to about 0.02% w/w BHT; about 0.005% to about 0.02% w/w BHA; about 0.25% to about 1 % w/w sodium CMC; about 0.1 % to about 0.5% w/w carnitine; about 0.5% to about 2% w/w glycerin; about 0.1 % to about 0.5% w/w erythritol; about 1 % to about 2% w/w trehalose; about 0.25% to about 1 % w/w boric acid; about 0.25% to about 1 % w/w polysorbate 80; about 0.1 % to about 1 % w/w POE 40 stearate; about 0.05% to about 0.25% 0.25% w/w acrylates/C 10-30
  • an ophthalmic composition comprising about 0.1 % to about 0.5% w/w flaxseed oil; about 0.1 % to about 0.5% w/w castor oil; about 0.005% to about 0.02% w/w BHT; about 0.25% to about 1 % w/w sodium CMC; about 0.1 % to about 0.5% w/w carnitine; about 0.5% to about 2% w/w glycerin; about 0.1 % to about 0.5% w/w erythritol; about 1 % to about 2% w/w trehalose; about 0.25% to about 1 % w/w boric acid; about 0.25% to about 1 % w/w polysorbate 80; about 0.1 % to about 1 % w/w POE 40 stearate; about 0.05% to about 0.25% w/w acrylates/C 10-30 alkyl acrylate crosspolymer; and water; and where
  • an ophthalmic composition comprising about 0.1 % to about 0.25% w/w flaxseed oil; about 0.1 % to about 0.25% w/w castor oil; about 0.005% to about 0.02% w/w BHT; about 0.005% to about 0.02% w/w BHA; about 0.25% to about 1 % w/w sodium CMC; about 0.1 % to about 0.5% w/w carnitine; about 0.5% to about 2% w/w glycerin; about 0.1 % to about 0.5% w/w erythritol; about 1 % to about 2% w/w trehalose; about 0.25% to about 1 % w/w boric acid; about 0.25% to about 1 % w/w polysorbate 80; about 0.1 % to about 1 % w/w POE 40 stearate; about 0.05% to about 0.25% w/w acrylates/C
  • an ophthalmic composition comprising about 0.1 % to about 0.25% w/w flaxseed oil; about 0.1 % to about 0.25% w/w castor oil; about 0.02% w/w BHT; about 0.25% to about 1 % w/w sodium CMC; about 0.1 % to about 0.5% w/w carnitine; about 0.5% to about 2% w/w glycerin; about 0.1 % to about 0.5% w/w erythritol; about 1 % to about 2% w/w trehalose; about 0.25% to about 1 % w/w boric acid; about 0.25% to about 1 % w/w polysorbate 80; about 0.1 % to about 1 % w/w POE 40 stearate; about 0.05% to about 0.25% w/w acrylates/C 10-30 alkyl acrylate crosspolymer; and water; and wherein the composition
  • an ophthalmic composition consisting essentially of about 0.125% w/w flaxseed oil; about 0.125% w/w castor oil; about 0.005% to about 0.02% w/w BHT; about 0.005% to about 0.02% w/w BHA; about 0.5% w/w sodium CMC; about 0.25% w/w carnitine; about 1 % w/w glycerin; about 0.25% w/w erythritol; about 1 .5% w/w trehalose; about 0.6% w/w boric acid; about 0.5% w/w polysorbate 80; about 0.25% to about 0.5% w/w POE 40 stearate; about 0.1 % w/w acrylates/C 10-30 alkyl acrylate crosspolymer; and water; and wherein the composition does not include an antimicrobial preservative.
  • an ophthalmic composition consisting essentially of about 0.125% w/w flaxseed oil; about 0.125% w/w castor oil; about 0.02% w/w BHT; about 0.5% w/w sodium CMC; about 0.25% w/w carnitine; about 1 % w/w glycerin; about 0.25% w/w erythritol; about 1 .5% w/w trehalose; about 0.6% w/w boric acid; about 0.5% w/w polysorbate 80; about 0.25% to about 0.5% w/w POE 40 stearate; about 0.1 % w/w acrylates/C 10-30 alkyl acrylate crosspolymer; and water; and wherein the composition does not include an antimicrobial preservative.
  • the ophthalmic composition comprises, consists essentially of, or consists of the specific exemplary emulsions provided in Tables 3-10 below.
  • the weight percentage may be approximate, meaning that each ingredient is present in about the weight percentage specified (i.e., the weight percentage may vary by the amounts as defined by "about” herein).
  • the weight percentage provided is exactly that provided.
  • compositions containing flaxseed oil (a.k.a., linseed oil) as the source of omega-3 fatty acids are listed in Table 3. These compositions were found to exhibit excellent chemical and physical stability. Other compositions with good
  • Example 1 The addition of BHA and BHT in the oil phase of an emulsion designated as "Formulation 5" improves the chemical stability of omega-3 oils in said emulsions as compared to "Formulation 4" which contains no BHA or BHT. See FIG. 1. Degradation of omega-3 oil is observed within two months in emulsions not containing BHA and BHT (OmE-B) stored at both room temperature and 40°C, while those containing BHA and BHT (OmE-C) are stable at all 3 temperatures during this period.
  • the composition of Formulation 4 and Formulation 5 is provided in Table 4 below. [0059] Table 4
  • Example 2 Addition of BHA and BHT in the oil phase improved physical stability to omega-3 oils in emulsion.
  • Formulation 6 containing only BHA/BHT in oil phase maintained its white opaque appearance at all storage conditions (5°C, 25°C and 40°C) over 3 months, while discoloration seen for emulsions containing a-tocopherol and ascorbyl palmitate over the same duration (Formulations 7 and 8).
  • Discoloration was found to be due to chemical degradation of omega-3 fatty acids. Data shown is for samples stored at 40°C for 3 months.
  • Example 3 Inclusion of excipients which are reported in literature as oil soluble antioxidants, such as alpha-tocopherol and vitamin-E-acetate, surprisingly worsened the chemical stability of omega-3 oils in emulsion. See FIG. 2. No significant impact of water soluble additives such as pyruvate or EDTA to the stability of omega-3 oils was observed.
  • the composition of each of the tested emulsions is provided in Table 10 at the end of these examples.
  • Example 4 Formulation compositions were optimized to select ingredients to provide maximum stability for the omega-3 emulsion compositions. Compositions of two exemplary lead formulations (Formulation 1 and Formulation 3) are shown in Table 6 below. [0064] Table 6
  • Formulation 3 98.0 106.3 101 3.9 90.17 89.33 102.82 98.42
  • Table 6 shows the chemical & physical stability of the exemplary formulations. Flaxseed oil analysis was done by LCMS by quantification of the triglyceride of linolenic acid (omega-3 component). No significant degradation of the triglyceride of linolenic acid was observed and all results were within analytical error for the method ( ⁇ 10%). Formulations 1 and 3 each remained white/translucent in color with no discoloration, creaming or oil separation after storage for 5 months at 25°C and 40°C. See Table 6.
  • Example 5 Globule size analysis of each of Formulation 1 and Formulation 3 was performed to further evaluate the stability of the omega-3 component. See Table 7 below. No changes in globule size of the emulsions was observed over the course of three months of stability monitoring. These results further confirm the stability of emulsions Formulations 1 and 3, and other similar omega-3 emulsions containing BHT and/or BHA.
  • Example 6 pH and osmolality analysis was performed to further evaluate the stability of the omega-3 components in the test formulations. See Table 8 below. The test formulations showed no changes over 3 months of stability monitoring,
  • Formulations 1 and 3 were found to be well- tolerated. See FIG. 3. While each was well-tolerated, Formulation 1 demonstrated the lowest discomfort score in vivo, showing that the emulsion was particularly well-tolerated.
  • Flaxseed Oil 0.125 0.125 0.25 0.125 0.125 0.125 0.125 0.125 0.125 0.125 0.125 0.125 0.125 0.125 0.125 0.125 0.125
  • POE 40 Stearate — 0.25 0.5 0.25 0.25 0.25 0.25 0.25 —
  • Polysorbate 80 0.5 0.5 0.5 — 0.5 0.5 0.25 0.5
  • kits for the diagnosis, treatment, or prevention of keratoconjunctivitis or dry eye syndrome are provided herein.
  • the methods of diagnosis, treatment, or prevention described herein may be performed by the topical application of a
  • composition provided herein directly to the eye or the surround tissue of the eye.
  • Abnormalities of the tear film include an absolute or partial deficiency in aqueous tear production is known as keratoconjunctivitis sicca, or KCS.
  • Keratoconjunctivitis sicca is typically caused by inadequate tear production.
  • the aqueous tear layer is affected, resulting in aqueous tear deficiency or lacrimal hyposecretion.
  • the lacrimal gland does not produce sufficient tears to keep the entire conjunctiva and cornea covered by a complete layer. This usually occurs in people who are otherwise healthy. Increased age is associated with decreased tearing. This is the most common type found in postmenopausal women.
  • causes include idiopathic, congenital alacrima, xerophthalmia, lacrimal gland ablation, and sensory denervation. In rare cases, it may be a symptom of collagen vascular diseases, including rheumatoid arthritis, Wegener's granulomatosis, and systemic lupus erythematosus.
  • the main symptom of keratoconjunctivitis sicca is a foreign body sensation or a mild scratchiness. This can progress to become a constant, intense burning or irritative sensation that can be debilitating to a patient. More severe forms can progress to the development of filamentary keratitis, a painful condition characterized by the appearance of numerous strands or filaments attached to the corneal surface. Evidence suggests that these filaments represent breaks in the continuity of normal corneal epithelial cells. The shear created by lid motion pulls these filaments, causing pain. Management of this stage of keratoconjunctivitis sicca is very difficult.
  • Keratoconjunctivitis sicca can develop in the absence of any other overt system abnormality, there is a frequent association of keratoconjunctivitis sicca with systemic disease. Keratoconjunctivitis sicca can occur as part of a larger systemic involvement known as Sjogren's syndrome. This classically consists of dry eyes, dry mouth and arthritis. Sjogren's syndrome and autoimmune diseases associated with Sjogren's syndrome are also conditions associated with aqueous tear deficiency. Drugs such as isotretinoin, sedatives, diuretics, tricyclic antidepressants, antihypertensives, oral contraceptives, antihistamines, nasal decongestants, beta-blockers,
  • phenothiazines, atropine, and pain relieving opiates such as morphine can cause or worsen this condition.
  • Infiltration of the lacrimal glands by sarcoidosis or tumors, or postradiation fibrosis of the lacrimal glands can also cause this condition.
  • Keratoconjunctivitis sicca can also be caused by abnormal tear composition resulting in rapid evaporation or premature destruction of the tears. When caused by rapid evaporation, it is termed evaporative dry eyes. In this condition, although the tear gland produces a sufficient amount of tears, the rate of evaporation of the tears is too rapid. There is a loss of water from the tears that results in tears that are too “salty” or hypertonic. As a result, the entire conjunctiva and cornea cannot be kept covered with a complete layer of tears during certain activities or in certain environments.
  • dry eye symptoms may be caused by aging as tear production tends to decrease with age. Dry eye may also be caused by injury to the eye, burns, diabetes, or by adenoviruses. Dry eye may also be caused by contact lens use or by ocular surgical procedures.
  • provided herein are methods for the treatment of keratoconjunctivitis sicca or dry eye syndrome in a human or other mammal, with or without therapeutic agents, as caused by any one or more of the above factors or other factors, using the ophthalmic compositions described herein. In some embodiments, provided herein are methods for the treatment of
  • keratoconjunctivitis sicca or dry eye syndrome in a human or other mammal, with or without therapeutic agents, as caused by any one or more of the above factors or other factors, by topical application of the ophthalmic compositions described herein.
  • treatment refers to an approach (e.g., a procedure or regimen) for obtaining beneficial or desired results, including clinical results.
  • Treating" a disease, disorder or condition means that the extent, undesirable clinical manifestations, or both, of a disease, disorder or condition are lessened and/or the time course of the progression is slowed (i.e., lengthened in time), as compared to not treating the disease, disorder or condition.
  • beneficial or desired clinical results include, but are not limited to, alleviation or amelioration of one or more symptoms (e.g., symptoms of dry eye syndrome), diminishment of extent of disorder, stabilized (i.e., not worsening) state of disorder, delay or slowing of disorder progression, amelioration or palliation of the disorder, and remission (whether partial or total), whether detectable or undetectable.
  • symptoms e.g., symptoms of dry eye syndrome
  • stabilized i.e., not worsening
  • delay or slowing of disorder progression e.e., amelioration or palliation of the disorder
  • remission whether partial or total
  • a therapeutically effective amount employed in a treatment is a sufficient amount to reduce the extent, undesirable clinical manifestation, of both, of a disease, disorder or condition.
  • LASIK laser in situ keratomileusis
  • other vision correction procedures can cause dry eyes after they penetrate the eye's surface and reduce corneal nerve sensitivity. In some cases, the eye then fails to sense the need for lubrication and inadequate tear production results. Therefore, provided herein are methods of treating dry eye incident to or induced by ocular surgery.
  • Ocular surgery includes, but is not limited to LASIK, small incision lenticule extraction (SMILE) procedures, and cataract procedures. See Ocul. Surf., 8: 135-145 (2010); Ophthamology, 107: 2131 -2135 (2000).
  • LASIK small incision lenticule extraction
  • SMILE small incision lenticule extraction
  • the method of treatment ameliorates the symptoms of post-LASIK tear dysfunction. In another embodiment, the method of treatment ameliorates the symptoms of post-cataract surgery tear dysfunction. In another embodiment, the method of treatment ameliorates the symptoms of post-SMILE surgery tear dysfunction.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Stabilized ophthalmic compositions containing omega-3 oils are provided, which are useful as artificial tears and as ophthalmic compositions to diagnose, treat, or prevent keratoconjunctivitis or dry eye syndrome in a human or other mammal.

Description

STABILIZED OMEGA-3 OPHTHALMIC COMPOSITIONS
By: Anuradha V. Gore, Jaya Giyanani and Sukhon Likitlersuang
CROSS REFERENCE
[0001] This application claims the benefit of U.S. Provisional Application Serial No. 62/083,980 filed on November 25, 2014, the disclosure of which is hereby incorporated in its entirety herein by reference.
FIELD
[0002] Provided herein are stabilized ophthalmic compositions containing omega-3 oils. Among other things, the compositions are useful as artificial tears and as ophthalmic compositions to diagnose, treat, or prevent dry eye syndrome or
keratoconjunctivitis in a human or other mammal in need of such diagnosis treatment, or prevention.
BACKGROUND
[0003] Omega-3 oils are widely noted in the published literature for their beneficial effects on ocular health, and certain omega-3 fatty acids are known to be significant components of the mammalian eye. See, e.g., Insight, Oct-Dec; 33(4): 20-5 (2008). A majority of omega-3 oil products are formulated as soft or hard gel capsules filled with omega-3 oil compositions which are intended for oral and systemic delivery of the omega-3 oils. Currently there are no commercial ophthalmic products in US market containing omega-3 oils for ocular surface delivery. Emulsions are typically the preferred dosage form for delivery of oily components to the surface of the eye, in which the oil dispersed in the water phase as droplets typically in the sub-micron range by using surfactants and emulsifiers.
[0004] A major hurdle in development of an ophthalmic product containing the omega-3 oils is the chemical stability of the omega-3 components which are susceptible degradation by oxidation and hydrolysis. U.S. Patent Publication Nos. 2007/0265341 , 2008/0153909 and 2010/0305045, for example, teach certain omega-3 oil containing compositions, but do not address this stability issue. U.S. 2007/0265341 teaches the use of vitamin E as an antioxidant, but vitamin E is not effective in preserving omega-3 oils as described herein. Thus, there is a need for stable ophthalmic compositions containing omega-3 oils.
SUMMARY
[0005] Provided herein are stabilized ophthalmic compositions containing omega-3 oils and one or more antioxidants. Specifically, the antioxidants are selected from butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT), alone or in combination. These compositions may be used, among other things, as artificial tears and as ophthalmic compositions to diagnose, treat, or prevent keratoconjunctivitis or dry eye syndrome in a human or other mammal in need of such diagnosis, treatment, or prevention.
BRIEF DESCRIPTION OF THE FIGURES
[0006] FIG. 1 shows the improved chemical stability of omega-3 oils in emulsions containing BHA and BHT, as compared to emulsions containing omega-3 oil without BHA/BHT.
[0007] FIG. 2 shows flaxseed oil emulsion formulation stability over time. [0008] FIG. 3 shows in vivo tolerability results of omega-3 oil emulsions.
DETAILED DESCRIPTION DETAILED DESCRIPTION
[0009] Provided herein are stabilized ophthalmic compositions containing omega-3 oils and one or more antioxidants. Specifically, the antioxidants are selected from butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT), alone or in combination.
[0010] Butylated hydroxytoluene (BHT) is also known as butylhydroxytoluene, tert- butylhydroxytoluene, or 2,6-bis(1 ,1-dimethylethyl)-4-methylphenol. Butylated
hydroxyanisole (BHA) is also known as butylhydroxyanisole or terf-butylhydroxyanisole. BHA commonly includes a mixture of 2-terf-butyl-4-hydroxyanisole and 3-terf-butyl-4- hydroxyanisole.
[001 1] The inventors surprising found that BHA, BHT, or combinations thereof exhibit a unique stabilizing effect on omega-3 oils as compared to other known antioxidants. A variety of ophthalmic compositions were evaluated which contained antioxidants with the intent to prevent the degradation of the omega-3 oil components. A common problem with omega-3 oils is their propensity to degrade and become rancid over time. Surprisingly, many commonly used antioxidants for oils such as ascorbyl palmitate, alpha tocopherol and Vitamin E acetate did not show beneficial effects in protecting the omega -3 components from degradation. Even more surprisingly, in some cases these antioxidants enhanced the degradation rates of the omega-3 oils. Only BHA and BHT were found to have a stabilizing effect on the omega-3 oils.
[0012] Utilizing this stabilizing property of BHA and BHT, several novel formulation compositions were developed for omega-3 oil containing ophthalmic emulsions.
Emulsion prototypes were designed using a range of excipients including different surfactants, antioxidants and aqueous additives. The physical and chemical stability of these prototype formulations were monitored over 3, 6 and/or 12 months at accelerated and/or long term storage conditions. It was found that emulsions containing BHA and/or BHT were chemically and physically stable for 3, 6 and/or 12 months at accelerated and/or long term storage conditions. The addition of other oil soluble antioxidants, such as Vitamin E acetate, ascorbyl palmitate and alpha-tocopherol led to degradation of omega-3 oil along with a change in physical appearance of the emulsions. Water soluble additives such as EDTA, trehalose and pyruvate did not impact stability for the emulsions. Details of these stability studies are provided in the examples herein.
[0013] The compositions provided herein may be used, among other things, as artificial tears and/or as ophthalmic compositions for the treatment of dry eye, or to diagnose, treat, or prevent keratoconjunctivitis or dry eye syndrome in man or other animals. The ophthalmic compositions provided herein may also include one or more therapeutic agents, in addition to one or more omega-3 oils.
[0014] In addition to the omega-3 oils and antioxidant selected from BHA, BHT and mixtures thereof, the ophthalmic compositions provided herein may contain other ingredients suitable for ophthalmic use. These compositions are also referred to as ophthalmically acceptable liquids. An ophthalmically acceptable liquid includes a liquid formulated to be tolerable to a patient for topical ophthalmic use. An ophthalmically acceptable liquid may be a solution or an emulsion.
[0015] For ophthalmic application, solutions or other forms of
compositions/medicaments may be prepared, for example, by using a physiological saline solution as a major vehicle. Ophthalmic solutions or compositions may be maintained at a comfortable pH with an appropriate buffer system. The formulations may also contain conventional, pharmaceutically acceptable preservatives, stabilizers and surfactants.
[0016] In some embodiments, the ophthalmic composition provided herein includes a buffer. The buffer may vary, and may include any weak conjugate acid-base pair suitable for maintaining a desirable pH range. Examples include, but are not limited to, acetate buffers, citrate buffers, phosphate buffers, borate buffers, or a combination thereof. Acids or bases may be used to adjust the pH of these formulations as needed. The amount of buffer used may vary. In some embodiments, the buffer may have a concentration in a range of about 1 nM to about 100 mM. The pH of a buffered solution may be increased by the addition of NaOH or another base, or decreased by the addition of HCI or another acid. In some embodiments, the pH of a composition may be about 6.4 to about 7.8; 6.8 to about 7.5; 6.8 to about 7.4; 6.8 to about 7.3; 6.8 to about 7.2; 6.9 to about 7.1 ; or about 6.8; about 6.9; about 7.0; about 7.1 ; about 7.2 or about 7.3.
[0017] An ophthalmic composition provided herein may include one or more surfactants. The surfactant may vary, and may include any compound that is surface active or can form micelles. A surfactant may be used for assisting in dissolving an excipient or an active agent, dispersing a solid or liquid in a composition, enhancing wetting, modifying drop size, stabilizing an emulsion, or a number of other purposes. Useful surfactants include, but are not limited to, surfactants of the following classes: alcohols; amine oxides; block polymers; carboxylated alcohol or alkylphenol
ethoxylates; carboxylic acids/fatty acids; ethoxylated alcohols; ethoxylated alkylphenols; ethoxylated aryl phenols; ethoxylated fatty acids; ethoxylated; fatty esters or oils (animal and vegetable); fatty esters; fatty acid methyl ester ethoxylates; glycerol esters; glycol esters; lanolin-based derivatives; lecithin and lecithin derivatives; lignin and lignin derivatives; methyl esters; monoglycerides and derivatives; polyethylene glycols;
polymeric surfactants; propoxylated and ethoxylated fatty acids, alcohols, or alkyl phenols; protein-based surfactants; sarcosine derivatives; sorbitan derivatives; sucrose and glucose esters and derivatives. In some embodiments, the surfactant may include polyethylene glycol (15)-hydroxystearate (CAS Number 70142-34-6, available as Solutol HS 15® from BASF), polyoxyethylene-polyoxypropylene block copolymer (CAS No. 9003-1 1 -6, available as Pluronic® F-68 from BASF), polyoxyethylene 40 stearate (POE 40 stearate), polysorbate 80 or polyoxyethylene (80) sorbitan monooleate (CAS No. 9005-65-6), sorbitane monostearate (CAS No. 1338-41-6, available as Span™ 60 from Croda International PLC), polyoxyethylenglyceroltriricinoleat 35 (CAS No. 61791 - 12-6, available as Cremophor EL® from BASF). The amount of surfactant may vary. In some embodiments, the amount of any surfactant such as those listed above may be about 0.001 to about 5%, about 0.1 % to about 2%, or about 0.1 % to about 1 %. [0018] An ophthalmic composition provided herein may include one or more viscosity modifying agents, including the class of hydrogel polymers. Examples of viscosity modifying agents include, but are not limited to, carboxymethyl cellulose (CMC) and salts thereof, cellulose polymers such as hydroxypropyl methyl cellulose (HPMC), alkyl acrylate crosspolymers such as a acrylates/C 10-30 alkyl acrylate crosspolymer (e.g. Pemulen™), polyvinylpyrrolidone (PVP), hyaluronic acid (HA) and salts thereof, hydroxyethyl cellulose (HEC), ethyl hydroxyethyl cellulose, hydroxypropyl cellulose, methyl cellulose, dextran 70, gelatin, glycerine, polyethylene glycols, polysorbate 80, propylene glycol, povidone, carbomers, polyvinyl alcohol, alginates, carrageenans, guar gum, karaya gum, agarose gum, locust bean gum, tragacanth gum and xanthan gum.
[0019] In some embodiments, the hydrogel polymer is selected from CMC and its salts, HPMC, PVP, HEC, HA and its salts, and mixtures thereof. In some embodiments, the hydrogel polymer is sodium CMC.
[0020] In some embodiments, the viscosity agent may be a combination of a hydrogel polymer and an alkyl acrylate crosspolymer, such as an acrylates/C 10-30 alkyl acrylate crosspolymer. Pemulen™ TR-2 (Lubrizol Corporation, Wickliffe, OH) is a commercially available acrylates/C 10-30 alkyl acrylate crosspolymer. In some embodiments, the amount of acrylates/C 10-30 alkyl acrylate crosspolymer is about 0.5% to about 1 .5%; or about 0.8% to about 1 .2%; or about 0.9% to about 1 .1 %; or about 1 .0%.
[0021] An ophthalmic composition provided herein may include one or more tonicity agents. The tonicity agent may vary, and may include any compound or substance useful for adjusting the tonicity of an ophthalmic liquid. Examples include, but are not limited to, salts, particularly sodium chloride, potassium chloride, magnesium chloride and calcium chloride; polyols and sugars such as glycerin (glycerol), propylene glycol, erythritol, mannitol, sorbitol and trehalose; amino acids such as carnitine (e.g., levocarnitine or L-carnitine) and betaine; or any other suitable ophthalmically acceptable tonicity adjustor. The amount of tonicity agent may vary depending upon whether an isotonic, hypertonic, or hypotonic liquid is desired. In some embodiments, the amount of a tonicity agent such as those listed above may be at least about 0.001 % up to about 1 %, about 2%, or about 5%. In some embodiments, the amount of each tonicity agent is about 0.125%, about 0.25%, about 0.4%, about 0.5%, about 0.6%, about 0.75%, about 1 .0%, about 1 .25%, about 1 .5%, about 1.75%, or about 2.0%
[0022] In some embodiments, the tonicity agents used herein to provide substantially isotonic, or slightly hypotonic, ophthalmically acceptable compositions. In some embodiments the osmolarity of the composition is 150 to 450 mOsm/kg; 250 to 330 mOsm/kg; 270 to 310 mOsm/kg; or about 240 mOsm/kg.
[0023] An ophthalmic composition provided herein may include one or more chelating agents. The chelating agent may vary, and may include any compound or substance that is capable of chelating a metal. A useful chelating agent is edetate disodium (EDTA), although other chelating agents may also be used in place or in conjunction with it.
[0024] While it is routine for ophthalmic solutions to contain antimicrobial
preservatives, the compositions provided herein do not contain such preservatives. Examples of such excluded preservatives include, but are not limited to, cationic preservatives such as quaternary ammonium compounds including benzalkonium chloride, polyquad, and the like; guanidine-based preservatives including PHMB, chlorhexidine, and the like; chlorobutanol; mercury preservatives such as thimerosal, phenylmercuric acetate and phenylmercuric nitrate; and oxidizing preservatives such as stabilized oxychloro complexes (e.g. Purite®).
[0025] Compositions provided herein may be aqueous solutions or emulsions, or some other acceptable liquid form. For an emulsion, one or more oils in addition to the omega-3 oils may be used to in the emulsion. Suitable oils include, but are not limited to anise oil, castor oil, clove oil, cassia oil, cinnamon oil, almond oil, corn oil, arachis oil, cottonseed oil, safflower oil, maize oil, linseed oil, rapeseed oil, soybean oil, olive oil, caraway oil, rosemary oil, peanut oil, peppermint oil, sunflower oil, eucalyptus oil, sesame oil, and the like. In certain embodiments, the addition oil is castor oil. [0026] Specific omega-3 oils include, but are not limited to, botanical oils such as linseed (flaxseed or linum usitatissimum), chia (chia sage or salvia hispanica), kiwifruit (Chinese gooseberry or actinidia chinensis), perilla (shiso or perilla frutescens), lingonberry (cowberry or vaccinium vitis-idaea), camelina (gold-of-pleasure or camelina sativa), purslane (portulaca or portulaca oleracea) and black raspberry {rubus occidentalis); and oils from cold water fish such as cod liver oil, salmon oil, anchovy oil and tuna oil. In certain embodiments, the omega-3 oil is flaxseed oil.
[0027] Table 1 : Exemplary omega-3 acids present in omega-3 oils
Common name i Lipid name Chemical name
Hexadecatrienoic acid (HTA) M 6:3 (n-3) all-cis-7, 10, 13-hexadecatrienoic acid
a-Linolenic acid (ALA) M 8:3 (n-3) all-cis-9, 12, 15-octadecatrienoic acid
Stearidonic acid (SDA) M 8:4 (n-3) all-cis-6,9, 12, 15-octadecatetraenoic acid
Eicosatrienoic acid (ETE) ! 20:3 (n-3) all-cis- 1 , 14, 17-eicosatrienoic acid
Eicosatetraenoic acid (ETA) 120:4 (n-3) all-cis-8, 1 1 , 14,17-eicosatetraenoic acid
Eicosapentaenoic acid (EPA) ! 20:5 (n-3) all-cis-5, 8,1 1 ,14, 17-eicosapentaenoic acid
Heneicosapentaenoic acid (HPA) 121 :5 (n-3) a//-c/'s-6,9,12,15,18-heneicosapentaenoic acid
Docosapentaenoic acid (DPA),
-3) all-cis-7, 10, 13, 16,19-docosapentaenoic acid Clupanodonic acid 122:5 (n
Docosahexaenoic acid (DHA) 122:6 (n-3) a//-c/'s-4,7,10,13,16,19-docosahexaenoic acid
Tetracosapentaenoic acid 124:5 (n-3) all-cis-9, 12, 15, 18,21 -tetracosapentaenoic acid
Tetracosahexaenoic acid (Nisinic acid) ; 24:6 (n-3) all-cis-6,9, 12, 15, 18,21 -tetracosahexaenoic acid
[0028] Any of the compositions provided herein may include, as an "omega-3 oil" one of the omega-3 acids of Table 1 or mixtures thereof, either from synthetic sources or as isolated from a natural oil.
[0029] Table 2 provides examples of plant seed oils which may be used as source of omega-3 components. One or more of the oils provided in Table 2 may be used as the omega-3 oil source for the emulsion formulations. [0030] Table 2
[0031 ] In specific embodiments, the ophthalmic compositions provided herein comprise one or more omega-3 oils, castor oil, BHT and/or BHA, one or more hydrogels, one or more tonicity agents, one or more surfactants, and an acrylates/C 10- 30 alkyl acrylate crosspolymer, and do not include an antimicrobial preservative.
[0032] In other embodiments, the ophthalmic compositions provided herein comprise flaxseed oil, castor oil, BHT and/or BHA, one or more hydrogels, one or more tonicity agents, one or more surfactants, and an acrylates/C 10-30 alkyl acrylate crosspolymer, and do not include an antimicrobial preservative.
[0033] In one embodiment, provided herein is an ophthalmic composition comprising flaxseed oil, castor oil, BHT, one or more hydrogels, one or more tonicity agents, one or more surfactants, and an acrylates/C 10-30 alkyl acrylate crosspolymer, and wherein the composition does not include an antimicrobial preservative.
[0034] In one embodiment, provided herein is an ophthalmic composition comprising flaxseed oil, castor oil, BHA, one or more hydrogels, one or more tonicity agents, one or more surfactants, and an acrylates/C 10-30 alkyl acrylate crosspolymer, and wherein the composition does not include an antimicrobial preservative.
[0035] In one embodiment, provided herein is an ophthalmic composition comprising flaxseed oil, castor oil, BHT, BHA, one or more hydrogels, one or more tonicity agents, one or more surfactants, and an acrylates/C10-30 alkyl acrylate crosspolymer, and wherein the composition does not include an antimicrobial preservative.
[0036] In one embodiment, provided herein is an ophthalmic composition comprising flaxseed oil; castor oil; BHT and/or BHA; CMC or a salt thereof; one or more tonicity agents; one or more surfactants; and an acrylates/C 10-30 alkyl acrylate crosspolymer; and wherein the composition does not include an antimicrobial preservative.
[0037] In one embodiment, provided herein is an ophthalmic composition comprising flaxseed oil; castor oil; BHT and/or BHA; CMC or a salt thereof; one or more tonicity agents selected from carnitine, glycerin, erythritol and trehalose; one or more
surfactants; and an acrylates/C10-30 alkyl acrylate crosspolymer; and wherein the composition does not include an antimicrobial preservative.
[0038] In one embodiment, provided herein is an ophthalmic composition comprising flaxseed oil; castor oil; BHT and/or BHA; CMC or a salt thereof; one or more tonicity agents selected from carnitine, glycerin, erythritol and trehalose; one or more
surfactants selected from polysorbate 80 and POE 40 stearate; and an acrylates/C 10- 30 alkyl acrylate crosspolymer; and wherein the composition does not include an antimicrobial preservative.
[0039] In one embodiment, provided herein is an ophthalmic composition comprising flaxseed oil; castor oil; BHT and/or BHA; sodium CMC; one or more tonicity agents selected from carnitine, glycerin, erythritol and trehalose; one or more surfactants selected from polysorbate 80 and POE 40 stearate; and an acrylates/C 10-30 alkyl acrylate crosspolymer; and wherein the composition does not include an antimicrobial preservative. [0040] In one embodiment, provided herein is an ophthalmic composition comprising flaxseed oil; castor oil; BHT and/or BHA; sodium CMC; one or more tonicity agents selected from carnitine, glycerin, erythritol and trehalose; polysorbate 80; POE 40 stearate; and an acrylates/C 10-30 alkyl acrylate crosspolymer; and wherein the composition does not include an antimicrobial preservative.
[0041] In one embodiment, provided herein is an ophthalmic composition comprising flaxseed oil; castor oil; BHT and/or BHA; sodium CMC; carnitine; glycerin; erythritol; trehalose; a buffer; polysorbate 80; POE 40 stearate; and an acrylates/C10-30 alkyl acrylate crosspolymer; and wherein the composition does not include an antimicrobial preservative.
[0042] In one embodiment, provided herein is an ophthalmic composition comprising flaxseed oil; castor oil; BHT and/or BHA; sodium CMC; carnitine; glycerin; erythritol; trehalose; boric acid; polysorbate 80; POE 40 stearate; and an acrylates/C 10-30 alkyl acrylate crosspolymer; and wherein the composition does not include an antimicrobial preservative.
[0043] In one embodiment, provided herein is an ophthalmic composition comprising flaxseed oil; castor oil; BHT; sodium CMC; carnitine; glycerin; erythritol; trehalose; boric acid; polysorbate 80; POE 40 stearate; an acrylates/C 10-30 alkyl acrylate crosspolymer; and water; and wherein the composition does not include an antimicrobial preservative.
[0044] In one embodiment, provided herein is an ophthalmic composition comprising flaxseed oil; castor oil; BHT; BHA; sodium CMC; carnitine; glycerin; erythritol; trehalose; boric acid; polysorbate 80; POE 40 stearate; an acrylates/C 10-30 alkyl acrylate crosspolymer; and water; and wherein the composition does not include an
antimicrobial preservative.
[0045] When the term "about" is used herein, it is understood to encompass a reasonable range of variation around the value provided. A reasonable variation is understood by those skilled in the art to depend on the art and the specific
circumstances of the defined value. In some embodiments, "about" includes a +/- 30% variation from the value provided. In some embodiments, "about" includes a +/- 25% variation from the value provided. In some embodiments, "about" includes a +/- 10% variation from the value provided. In some embodiments, "about" includes a +/- 5% variation from the value provided. In some embodiments, "about" includes a +/- 1 % variation from the value provided.
[0046] In one embodiment, provided herein is an ophthalmic composition comprising about 0.1 % to about 1 % w/w flaxseed oil; about 0.1 % to about 1 % w/w castor oil; about 0.001 % to about 0.05% w/w BHT; about 0.001 % to about 0.05% w/w BHA; about 0.25% to about 1 % w/w sodium CMC; about 0.1 % to about 0.5% w/w carnitine; about 0.1 % to about 2% w/w glycerin; about 0.1 % to about 0.5% w/w erythritol; about 0.5% to about 3% w/w trehalose; about 0.1 % to about 2% w/w boric acid; about 0.1 % to about 2% w/w polysorbate 80; about 0.1 % to about 2% w/w POE 40 stearate; about 0.1 % to about 1 % w/w acrylates/C10-30 alkyl acrylate crosspolymer; and water; and wherein the composition does not include an antimicrobial preservative.
[0047] In one embodiment, provided herein is an ophthalmic composition comprising about 0.1 % to about 1 % w/w flaxseed oil; about 0.1 % to about 1 % w/w castor oil; about 0.001 % to about 0.05% w/w BHT; about 0.25% to about 1 % w/w sodium CMC; about 0.1 % to about 0.5% w/w carnitine; about 0.1 % to about 2% w/w glycerin; about 0.1 % to about 0.5% w/w erythritol; about 0.5% to about 3% w/w trehalose; about 0.1 % to about 2% w/w boric acid; about 0.1 % to about 2% w/w polysorbate 80; about 0.1 % to about 2% w/w POE 40 stearate; about 0.05% to about 1 % w/w acrylates/C 10-30 alkyl acrylate crosspolymer; and water; and wherein the composition does not include an
antimicrobial preservative.
[0048] In one embodiment, provided herein is an ophthalmic composition comprising about 0.1 % to about 0.5% w/w flaxseed oil; about 0.1 % to about 0.5% w/w castor oil; about 0.005% to about 0.02% w/w BHT; about 0.005% to about 0.02% w/w BHA; about 0.25% to about 1 % w/w sodium CMC; about 0.1 % to about 0.5% w/w carnitine; about 0.5% to about 2% w/w glycerin; about 0.1 % to about 0.5% w/w erythritol; about 1 % to about 2% w/w trehalose; about 0.25% to about 1 % w/w boric acid; about 0.25% to about 1 % w/w polysorbate 80; about 0.1 % to about 1 % w/w POE 40 stearate; about 0.05% to about 0.25% w/w acrylates/C 10-30 alkyl acrylate crosspolymer; and water; and wherein the composition does not include an antimicrobial preservative.
[0049] In one embodiment, provided herein is an ophthalmic composition comprising about 0.1 % to about 0.5% w/w flaxseed oil; about 0.1 % to about 0.5% w/w castor oil; about 0.005% to about 0.02% w/w BHT; about 0.25% to about 1 % w/w sodium CMC; about 0.1 % to about 0.5% w/w carnitine; about 0.5% to about 2% w/w glycerin; about 0.1 % to about 0.5% w/w erythritol; about 1 % to about 2% w/w trehalose; about 0.25% to about 1 % w/w boric acid; about 0.25% to about 1 % w/w polysorbate 80; about 0.1 % to about 1 % w/w POE 40 stearate; about 0.05% to about 0.25% w/w acrylates/C 10-30 alkyl acrylate crosspolymer; and water; and wherein the composition does not include an antimicrobial preservative.
[0050] In one embodiment, provided herein is an ophthalmic composition comprising about 0.1 % to about 0.25% w/w flaxseed oil; about 0.1 % to about 0.25% w/w castor oil; about 0.005% to about 0.02% w/w BHT; about 0.005% to about 0.02% w/w BHA; about 0.25% to about 1 % w/w sodium CMC; about 0.1 % to about 0.5% w/w carnitine; about 0.5% to about 2% w/w glycerin; about 0.1 % to about 0.5% w/w erythritol; about 1 % to about 2% w/w trehalose; about 0.25% to about 1 % w/w boric acid; about 0.25% to about 1 % w/w polysorbate 80; about 0.1 % to about 1 % w/w POE 40 stearate; about 0.05% to about 0.25% w/w acrylates/C 10-30 alkyl acrylate crosspolymer; and water; and wherein the composition does not include an antimicrobial preservative.
[0051] In one embodiment, provided herein is an ophthalmic composition comprising about 0.1 % to about 0.25% w/w flaxseed oil; about 0.1 % to about 0.25% w/w castor oil; about 0.02% w/w BHT; about 0.25% to about 1 % w/w sodium CMC; about 0.1 % to about 0.5% w/w carnitine; about 0.5% to about 2% w/w glycerin; about 0.1 % to about 0.5% w/w erythritol; about 1 % to about 2% w/w trehalose; about 0.25% to about 1 % w/w boric acid; about 0.25% to about 1 % w/w polysorbate 80; about 0.1 % to about 1 % w/w POE 40 stearate; about 0.05% to about 0.25% w/w acrylates/C 10-30 alkyl acrylate crosspolymer; and water; and wherein the composition does not include an
antimicrobial preservative.
[0052] In one embodiment, provided herein is an ophthalmic composition consisting essentially of about 0.125% w/w flaxseed oil; about 0.125% w/w castor oil; about 0.005% to about 0.02% w/w BHT; about 0.005% to about 0.02% w/w BHA; about 0.5% w/w sodium CMC; about 0.25% w/w carnitine; about 1 % w/w glycerin; about 0.25% w/w erythritol; about 1 .5% w/w trehalose; about 0.6% w/w boric acid; about 0.5% w/w polysorbate 80; about 0.25% to about 0.5% w/w POE 40 stearate; about 0.1 % w/w acrylates/C 10-30 alkyl acrylate crosspolymer; and water; and wherein the composition does not include an antimicrobial preservative.
[0053] In one embodiment, provided herein is an ophthalmic composition consisting essentially of about 0.125% w/w flaxseed oil; about 0.125% w/w castor oil; about 0.02% w/w BHT; about 0.5% w/w sodium CMC; about 0.25% w/w carnitine; about 1 % w/w glycerin; about 0.25% w/w erythritol; about 1 .5% w/w trehalose; about 0.6% w/w boric acid; about 0.5% w/w polysorbate 80; about 0.25% to about 0.5% w/w POE 40 stearate; about 0.1 % w/w acrylates/C 10-30 alkyl acrylate crosspolymer; and water; and wherein the composition does not include an antimicrobial preservative.
[0054] In other embodiments, the ophthalmic composition comprises, consists essentially of, or consists of the specific exemplary emulsions provided in Tables 3-10 below. In each instance, the weight percentage may be approximate, meaning that each ingredient is present in about the weight percentage specified (i.e., the weight percentage may vary by the amounts as defined by "about" herein). In other
embodiments, the weight percentage provided is exactly that provided.
[0055] Specific compositions containing flaxseed oil (a.k.a., linseed oil) as the source of omega-3 fatty acids are listed in Table 3. These compositions were found to exhibit excellent chemical and physical stability. Other compositions with good
chemical/physical stability are provided in the examples that follow. [0056] Table 3:
EXAMPLES
[0057] The following non-limiting examples are made for illustrative purposes. Each example represents at least one embodiment provided herein.
[0058] Example 1 : The addition of BHA and BHT in the oil phase of an emulsion designated as "Formulation 5" improves the chemical stability of omega-3 oils in said emulsions as compared to "Formulation 4" which contains no BHA or BHT. See FIG. 1. Degradation of omega-3 oil is observed within two months in emulsions not containing BHA and BHT (OmE-B) stored at both room temperature and 40°C, while those containing BHA and BHT (OmE-C) are stable at all 3 temperatures during this period. The composition of Formulation 4 and Formulation 5 is provided in Table 4 below. [0059] Table 4
[0060] Example 2: Addition of BHA and BHT in the oil phase improved physical stability to omega-3 oils in emulsion. Formulation 6 containing only BHA/BHT in oil phase maintained its white opaque appearance at all storage conditions (5°C, 25°C and 40°C) over 3 months, while discoloration seen for emulsions containing a-tocopherol and ascorbyl palmitate over the same duration (Formulations 7 and 8). Discoloration was found to be due to chemical degradation of omega-3 fatty acids. Data shown is for samples stored at 40°C for 3 months.
[0061] Table s
[0062] Example 3: Inclusion of excipients which are reported in literature as oil soluble antioxidants, such as alpha-tocopherol and vitamin-E-acetate, surprisingly worsened the chemical stability of omega-3 oils in emulsion. See FIG. 2. No significant impact of water soluble additives such as pyruvate or EDTA to the stability of omega-3 oils was observed. The composition of each of the tested emulsions is provided in Table 10 at the end of these examples.
[0063] Example 4: Formulation compositions were optimized to select ingredients to provide maximum stability for the omega-3 emulsion compositions. Compositions of two exemplary lead formulations (Formulation 1 and Formulation 3) are shown in Table 6 below. [0064] Table 6
Test Flaxseed Oil (% linolenic oil)
Timepoint
0 1 month 2 months 3 months
Condition
25°C 25°C 40 °C 25°C 40°C 25°C 40°C
Formulation 1 100.2 110.6 10« Ϊ.9 101.41 89.00 99.06 89.86
Formulation 3 98.0 106.3 101 3.9 90.17 89.33 102.82 98.42
[0065] Table 6 shows the chemical & physical stability of the exemplary formulations. Flaxseed oil analysis was done by LCMS by quantification of the triglyceride of linolenic acid (omega-3 component). No significant degradation of the triglyceride of linolenic acid was observed and all results were within analytical error for the method (±10%). Formulations 1 and 3 each remained white/translucent in color with no discoloration, creaming or oil separation after storage for 5 months at 25°C and 40°C. See Table 6.
[0066] Example 5: Globule size analysis of each of Formulation 1 and Formulation 3 was performed to further evaluate the stability of the omega-3 component. See Table 7 below. No changes in globule size of the emulsions was observed over the course of three months of stability monitoring. These results further confirm the stability of emulsions Formulations 1 and 3, and other similar omega-3 emulsions containing BHT and/or BHA.
[0067] Table 7
[0068] Example 6: pH and osmolality analysis was performed to further evaluate the stability of the omega-3 components in the test formulations. See Table 8 below. The test formulations showed no changes over 3 months of stability monitoring,
demonstrating chemical and physical stability of the omega-3 emulsions.
[0069] Tolerability of the test emulsions were evaluated in a rabbit model.
Formulations 1 and 3 were found to be well- tolerated. See FIG. 3. While each was well-tolerated, Formulation 1 demonstrated the lowest discomfort score in vivo, showing that the emulsion was particularly well-tolerated.
[0070] Table 8
[0071] Table 9
Formulation # 8 9 10 11 12 13 14 15
Ingredients (%w/w)
Glycerin 1 1 1 1 1 1 1 1
Sodium CMC 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5
Flaxseed Oil 0.125 0.125 0.25 0.125 0.125 0.125 0.125 0.125
Castor Oil 0.125 0.125 0.25 0.125 0.125 0.125 0.125 0.125
Solutol — — — 0.25 — — — —
POE 40 Stearate — 0.25 0.5 0.25 0.25 0.25 0.25 —
Polysorbate 80 0.5 0.5 0.5 — 0.5 0.5 0.25 0.5
BHA 0.02 0.02 0.02 0.02 — 0.005 0.02 0.02
BHT 0.02 0.02 0.02 0.02 0.02 0.005 0.02 0.02
Pemulen 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1
L-Carnitine 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25
Erythritol 0.25 0.25 0.25 0.25 0.25 0.25 0.5 0.5
Trehalose 1.5 1.5 1.5 1.5 1.5 1.5 — —
Boric Acid 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6
Water qs qs qs qs qs qs qs qs [0072] Table 10a
[0073] Table 10b
Methods of Treatment
[0074] Provided herein are methods for the diagnosis, treatment, or prevention of keratoconjunctivitis or dry eye syndrome. The methods of diagnosis, treatment, or prevention described herein may be performed by the topical application of a
composition provided herein directly to the eye or the surround tissue of the eye.
[0075] Abnormalities of the tear film include an absolute or partial deficiency in aqueous tear production is known as keratoconjunctivitis sicca, or KCS.
Keratoconjunctivitis sicca is typically caused by inadequate tear production. The aqueous tear layer is affected, resulting in aqueous tear deficiency or lacrimal hyposecretion. The lacrimal gland does not produce sufficient tears to keep the entire conjunctiva and cornea covered by a complete layer. This usually occurs in people who are otherwise healthy. Increased age is associated with decreased tearing. This is the most common type found in postmenopausal women. Causes include idiopathic, congenital alacrima, xerophthalmia, lacrimal gland ablation, and sensory denervation. In rare cases, it may be a symptom of collagen vascular diseases, including rheumatoid arthritis, Wegener's granulomatosis, and systemic lupus erythematosus.
[0076] In relatively mild cases, the main symptom of keratoconjunctivitis sicca is a foreign body sensation or a mild scratchiness. This can progress to become a constant, intense burning or irritative sensation that can be debilitating to a patient. More severe forms can progress to the development of filamentary keratitis, a painful condition characterized by the appearance of numerous strands or filaments attached to the corneal surface. Evidence suggests that these filaments represent breaks in the continuity of normal corneal epithelial cells. The shear created by lid motion pulls these filaments, causing pain. Management of this stage of keratoconjunctivitis sicca is very difficult.
[0077] A frequent complication of keratoconjunctivitis sicca is secondary infection.
Several breakdowns in the eye's normal defense mechanisms seem to occur, presumably attributable to a decrease in the concentration of antibacterial lysozyme in the aqueous tears of a patient suffering from keratoconjunctivitis sicca.
[0078] Although keratoconjunctivitis sicca can develop in the absence of any other overt system abnormality, there is a frequent association of keratoconjunctivitis sicca with systemic disease. Keratoconjunctivitis sicca can occur as part of a larger systemic involvement known as Sjogren's syndrome. This classically consists of dry eyes, dry mouth and arthritis. Sjogren's syndrome and autoimmune diseases associated with Sjogren's syndrome are also conditions associated with aqueous tear deficiency. Drugs such as isotretinoin, sedatives, diuretics, tricyclic antidepressants, antihypertensives, oral contraceptives, antihistamines, nasal decongestants, beta-blockers,
phenothiazines, atropine, and pain relieving opiates such as morphine can cause or worsen this condition. Infiltration of the lacrimal glands by sarcoidosis or tumors, or postradiation fibrosis of the lacrimal glands can also cause this condition. Histologically, in keratoconjunctivitis sicca (as part of Sjogren's syndrome or in isolation), the initial changes seen in the lacrimal glands are those of focal lymphocytic and plasma cell infiltrates associated with degeneration of glandular tissue. These changes resemble those seen in autoimmune disease in other tissue, giving rise to the speculation that keratoconjunctivitis sicca has an autoimmune basis.
[0079] Keratoconjunctivitis sicca can also be caused by abnormal tear composition resulting in rapid evaporation or premature destruction of the tears. When caused by rapid evaporation, it is termed evaporative dry eyes. In this condition, although the tear gland produces a sufficient amount of tears, the rate of evaporation of the tears is too rapid. There is a loss of water from the tears that results in tears that are too "salty" or hypertonic. As a result, the entire conjunctiva and cornea cannot be kept covered with a complete layer of tears during certain activities or in certain environments.
[0080] In general, dry eye symptoms may be caused by aging as tear production tends to decrease with age. Dry eye may also be caused by injury to the eye, burns, diabetes, or by adenoviruses. Dry eye may also be caused by contact lens use or by ocular surgical procedures.
[0081] Therefore, in some embodiments, provided herein are methods for the treatment of keratoconjunctivitis sicca or dry eye syndrome in a human or other mammal, with or without therapeutic agents, as caused by any one or more of the above factors or other factors, using the ophthalmic compositions described herein. In some embodiments, provided herein are methods for the treatment of
keratoconjunctivitis sicca or dry eye syndrome in a human or other mammal, with or without therapeutic agents, as caused by any one or more of the above factors or other factors, by topical application of the ophthalmic compositions described herein.
[0082] As provided herein, the term "treatment" as used herein refers to an approach (e.g., a procedure or regimen) for obtaining beneficial or desired results, including clinical results. "Treating" a disease, disorder or condition means that the extent, undesirable clinical manifestations, or both, of a disease, disorder or condition are lessened and/or the time course of the progression is slowed (i.e., lengthened in time), as compared to not treating the disease, disorder or condition. For purposes of the methods disclosed herein, beneficial or desired clinical results include, but are not limited to, alleviation or amelioration of one or more symptoms (e.g., symptoms of dry eye syndrome), diminishment of extent of disorder, stabilized (i.e., not worsening) state of disorder, delay or slowing of disorder progression, amelioration or palliation of the disorder, and remission (whether partial or total), whether detectable or undetectable.
[0083] As provided herein, the terms "effective amount," "therapeutically effective amount" and the like in the context of compositions and methods disclosed herein refer in the customary sense to an amount which is sufficient to bring about a desired result. Accordingly, a therapeutically effective amount employed in a treatment is a sufficient amount to reduce the extent, undesirable clinical manifestation, of both, of a disease, disorder or condition. [0084] LASIK (laser in situ keratomileusis) and other vision correction procedures can cause dry eyes after they penetrate the eye's surface and reduce corneal nerve sensitivity. In some cases, the eye then fails to sense the need for lubrication and inadequate tear production results. Therefore, provided herein are methods of treating dry eye incident to or induced by ocular surgery. Ocular surgery includes, but is not limited to LASIK, small incision lenticule extraction (SMILE) procedures, and cataract procedures. See Ocul. Surf., 8: 135-145 (2010); Ophthamology, 107: 2131 -2135 (2000).
[0085] In one embodiment, the method of treatment ameliorates the symptoms of post-LASIK tear dysfunction. In another embodiment, the method of treatment ameliorates the symptoms of post-cataract surgery tear dysfunction. In another embodiment, the method of treatment ameliorates the symptoms of post-SMILE surgery tear dysfunction.
[0086] The terms "a," "an," "the" and similar referents used herein (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., "such as") provided herein is intended merely to better illuminate the invention and does not pose a limitation on the scope of any claim. No language in the specification should be construed as indicating any non-claimed element essential to the practice of the invention.
[0087] Groupings of alternative elements or embodiments disclosed herein are not to be construed as limitations. Each group member may be referred to and claimed individually or in any combination with other members of the group or other elements found herein. It is anticipated that one or more members of a group may be included in, or deleted from, a group for reasons of convenience and/or patentability. When any such inclusion or deletion occurs, the specification is deemed to contain the group as modified thus fulfilling the written description of all Markush groups used in the appended claims.
[0088] In closing, it is to be understood that the embodiments disclosed herein are illustrative of the principles of the claims. Other modifications that may be employed are within the scope of the claims. Thus, by way of example, but not of limitation, alternative embodiments may be utilized in accordance with the teachings herein.
Accordingly, the claims are not limited to embodiments precisely as shown and described.

Claims

What is claimed is:
1 . An ophthalmic composition comprising one or more omega-3 oils; BHT and/or BHA; one or more hydrogels; one or more tonicity agents; one or more surfactants; and an acrylates/C 10-30 alkyl acrylate crosspolymer; and
wherein the ophthalmic composition does not include an antimicrobial preservative.
2. The ophthalmic composition of claim 1 , wherein the composition does not include BHA.
3. The ophthalmic composition of claim 1 or 2, wherein the omega-3 oil is selected
from the group consisting of flaxseed oil, chia oil, kiwifruit oil, perilla oil, lingonberry oil, camelina oil, purslane oil, black raspberry oil, cod liver oil, salmon oil, anchovy oil and tuna oil.
4. The ophthalmic composition of claim 1 or 2, wherein the omega-3 oil is flaxseed oil.
5. The ophthalmic composition of claim 4, wherein the flaxseed oil is present at a
concentration of about 0.1 % or about 1 % w/w.
6. The ophthalmic composition of any one of claims 1 -5, wherein the composition
further comprises castor oil.
7. The ophthalmic composition of claim 6, wherein the castor oil is present at a
concentration of about 0.1 % or about 1 % w/w.
8. The ophthalmic composition of any one of claims 1 -7, wherein the hydrogel is
carboxymethyl cellulose or a salt thereof.
9. The ophthalmic composition of any one of claims 1 -8, wherein the one or more
tonicity agents are selected from carnitine, glycerin, erythritol and trehalose.
10. The ophthalmic composition of any one of claims 1 -9, wherein the ophthalmic composition includes carnitine, glycerin, erythritol and trehalose.
1 1 .The ophthalmic composition of any one of claims 1 -10, wherein the one or more surfactants are selected from polysorbate 80, POE 40 stearate, and polyethylene glycol (15)-hydroxystearate.
12. The ophthalmic composition of claim 1 1 , wherein the surfactant is polysorbate 80.
13. The ophthalmic composition of claim 1 1 , wherein the surfactant is POE 40 stearate.
14. The ophthalmic composition of claim 1 1 , wherein the surfactants are polysorbate 80 and POE 40 stearate.
15. The ophthalmic composition of claim 1 1 , wherein the surfactants are polyethylene glycol (15)-hydroxystearate and POE 40 stearate.
16. The ophthalmic composition of any one of claims 1 -15, wherein the ophthalmic
composition further comprises a buffer.
17. The ophthalmic composition of claim 16, wherein the buffer is boric acid.
18. An ophthalmic composition comprising about 0.1 % to about 1 % w/w flaxseed oil; about 0.1 % to about 1 % w/w castor oil; about 0.001 % to about 0.05% w/w BHT; about 0.25% to about 1 % w/w sodium CMC; about 0.1 % to about 0.5% w/w carnitine; about 0.1 % to about 2% w/w glycerin; about 0.1 % to about 0.5% w/w erythritol; about 0.5% to about 3% w/w trehalose; about 0.1 % to about 2% w/w boric acid; about 0.1 % to about 2% w/w polysorbate 80; about 0.1 % to about 2% w/w POE 40 stearate; about 0.05% to about 1 % w/w acrylates/C 10-30 alkyl acrylate crosspolymer; and water; and wherein the composition does not include an antimicrobial preservative.
19. The ophthalmic composition of claim 13, wherein the composition comprises about 0.1 % to about 0.5% w/w flaxseed oil; about 0.1 % to about 0.5% w/w castor oil; about 0.005% to about 0.02% w/w BHT; about 0.25% to about 1 % w/w sodium CMC; about 0.1 % to about 0.5% w/w carnitine; about 0.5% to about 2% w/w glycerin; about 0.1 % to about 0.5% w/w erythritol; about 1 % to about 2% w/w trehalose; about 0.25% to about 1 % w/w boric acid; about 0.25% to about 1 % w/w polysorbate 80; about 0.1 % to about 1 % w/w POE 40 stearate; and about 0.05% to about 0.25% w/w acrylates/C 10-30 alkyl acrylate crosspolymer.
20. The ophthalmic composition of claim 13, wherein the composition comprises about 0.1 % to about 0.25% w/w flaxseed oil; about 0.1 % to about 0.25% w/w castor oil; about 0.02% w/w BHT; about 0.25% to about 1 % w/w sodium CMC; about 0.1 % to about 0.5% w/w carnitine; about 0.5% to about 2% w/w glycerin; about 0.1 % to about 0.5% w/w erythritol; about 1 % to about 2% w/w trehalose; about 0.25% to about 1 % w/w boric acid; about 0.25% to about 1 % w/w polysorbate 80; about 0.1 % to about 1 % w/w POE 40 stearate; and about 0.05% to about 0.25% w/w acrylates/C 10-30 alkyl acrylate crosspolymer.
21 . An ophthalmic composition comprising about 0.1 % to about 1 % w/w flaxseed oil; about 0.1 % to about 1 % w/w castor oil; about 0.001 % to about 0.05% w/w BHT; about 0.001 % to about 0.05% w/w BHA; about 0.25% to about 1 % w/w sodium CMC; about 0.1 % to about 0.5% w/w carnitine; about 0.1 % to about 2% w/w glycerin; about 0.1 % to about 0.5% w/w erythritol; about 0.5% to about 3% w/w trehalose; about 0.1 % to about 2% w/w boric acid; about 0.1 % to about 2% w/w polysorbate 80; about 0.1 % to about 2% w/w POE 40 stearate; about 0.1 % to about 1 % w/w acrylates/C 10-30 alkyl acrylate crosspolymer; and water; and wherein the composition does not include an
antimicrobial preservative.
22. The ophthalmic composition of claim 16, wherein the composition comprises about 0.1 % to about 0.5% w/w flaxseed oil; about 0.1 % to about 0.5% w/w castor oil; about
0.005% to about 0.02% w/w BHT; about 0.005% to about 0.02% w/w BHA; about 0.25% to about 1 % w/w sodium CMC; about 0.1 % to about 0.5% w/w carnitine; about 0.5% to about 2% w/w glycerin; about 0.1 % to about 0.5% w/w erythritol; about 1 % to about 2% w/w trehalose; about 0.25% to about 1 % w/w boric acid; about 0.25% to about 1 % w/w polysorbate 80; about 0.1 % to about 1 % w/w POE 40 stearate; and about 0.05% to about 0.25% w/w acrylates/C 10-30 alkyl acrylate crosspolymer.
23. The ophthalmic composition of claim 16, wherein the composition comprises about 0.1 % to about 0.25% w/w flaxseed oil; about 0.1 % to about 0.25% w/w castor oil; about 0.005% to about 0.02% w/w BHT; about 0.005% to about 0.02% w/w BHA; about 0.25% to about 1 % w/w sodium CMC; about 0.1 % to about 0.5% w/w carnitine; about 0.5% to about 2% w/w glycerin; about 0.1 % to about 0.5% w/w erythritol; about 1 % to about 2% w/w trehalose; about 0.25% to about 1 % w/w boric acid; about 0.25% to about 1 % w/w polysorbate 80; about 0.1 % to about 1 % w/w POE 40 stearate; and about 0.05% to about 0.25% w/w acrylates/C 10-30 alkyl acrylate crosspolymer.
24. A method of treating keratoconjunctivitis sicca or dry eye syndrome in a human or other mammal, the method comprising administering an effective amount of an ophthalmic composition according to any one of claims 1 -18 to said human or other mammal.
25. The method of claim 19, wherein amount of the ophthalmic composition is effective to reduce one or more symptoms of keratoconjunctivitis sicca or dry eye syndrome.
EP15805372.8A 2014-11-25 2015-11-23 Stabilized omega-3 ophthalmic compositions Pending EP3223794A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462083980P 2014-11-25 2014-11-25
PCT/US2015/062213 WO2016085885A1 (en) 2014-11-25 2015-11-23 Stabilized omega-3 ophthalmic compositions

Publications (1)

Publication Number Publication Date
EP3223794A1 true EP3223794A1 (en) 2017-10-04

Family

ID=54784036

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15805372.8A Pending EP3223794A1 (en) 2014-11-25 2015-11-23 Stabilized omega-3 ophthalmic compositions

Country Status (17)

Country Link
US (4) US10279005B2 (en)
EP (1) EP3223794A1 (en)
JP (1) JP6768653B2 (en)
KR (1) KR102487299B1 (en)
CN (1) CN107106483B (en)
AU (1) AU2015353701B2 (en)
CA (1) CA2967413C (en)
CL (1) CL2017001301A1 (en)
CO (1) CO2017005624A2 (en)
IL (1) IL252161B (en)
MX (2) MX2017006474A (en)
NZ (1) NZ732058A (en)
PH (1) PH12017500922A1 (en)
RU (1) RU2697844C9 (en)
SG (1) SG11201704167PA (en)
UA (1) UA121399C2 (en)
WO (1) WO2016085885A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018035469A1 (en) * 2016-08-19 2018-02-22 Akrivista, LLC Methods of diagnosing and treating dry eye syndrome and compositions for treating a human eye
CN111295169A (en) 2017-08-18 2020-06-16 阿克里维斯塔有限责任公司 Methods of diagnosing and treating dry eye syndrome and compositions for treating human eyes
AU2018323861B2 (en) 2017-08-27 2023-08-17 Rhodes Technologies Pharmaceutical compositions for the treatment of ophthalmic conditions
CN109364153A (en) * 2018-11-30 2019-02-22 河南科高中标检测技术有限公司 A kind of composition, the preparation method and applications of alleviation and treatment electron radiation class visual fatigue
EP3962621A4 (en) 2019-05-02 2022-11-30 Tearclear Corp. Preservative removal from eye drops
MX2022007389A (en) 2019-12-19 2022-08-10 Tearclear Corp Preservative removal from eye drops.
KR102365008B1 (en) * 2020-06-23 2022-02-23 주식회사태준제약 Ophthalmic Composition Comprising Diquafosol
KR102365009B1 (en) * 2020-06-23 2022-02-23 주식회사태준제약 Ophthalmic Composition Comprising Diquafosol
MX2023001557A (en) 2020-08-05 2023-03-08 Tearclear Corp Systems and methods for preservative removal from ophthalmic formulations.
US11951123B2 (en) 2022-01-12 2024-04-09 Platform Ophthalmic Innovations, LLC Fortified nutritional lubricating drops for dry eye disease

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4201706A (en) 1978-09-22 1980-05-06 Burton, Parsons & Company, Inc. Treatment of corneal edema
EP0028110B1 (en) 1979-10-26 1984-03-07 Smith and Nephew Associated Companies p.l.c. Autoclavable emulsions
JPS56104814A (en) 1980-01-25 1981-08-20 Kunihiro Okanoe Preparation of eye drop
US4649047A (en) 1985-03-19 1987-03-10 University Of Georgia Research Foundation, Inc. Ophthalmic treatment by topical administration of cyclosporin
DE3851152T2 (en) 1987-09-03 1995-01-26 Univ Georgia CYCLOSPORINE EYE PRODUCTS.
US4839342A (en) 1987-09-03 1989-06-13 University Of Georgia Research Foundation, Inc. Method of increasing tear production by topical administration of cyclosporin
FR2638089A1 (en) 1988-10-26 1990-04-27 Sandoz Sa NOVEL OPHTHALMIC COMPOSITIONS BASED ON CYCLOSPORINE
IT1224795B (en) 1988-12-01 1990-10-24 Sigma Tau Ind Farmaceuti USE OF ACETYL D-CARNITINE IN THE THERAPEUTIC TREATMENT OF GLAUCOMA AND PHARMACEUTICAL COMPOSITIONS USEFUL IN SUCH TREATMENT
JPH0723302B1 (en) 1989-08-03 1995-03-15
US5681555A (en) 1991-04-22 1997-10-28 Gleich; Gerald J. Method for the treatment of bronchial asthma by parenteral administration of anionic polymers
DE4229494A1 (en) 1992-09-04 1994-03-10 Basotherm Gmbh Medicines for topical use on the eye to treat increased intraocular pressure
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
KR970705985A (en) 1994-09-14 1997-11-03 우에하라 아끼라 Eye Drops for Repair Corneal Disturbance
US5980865A (en) 1995-08-18 1999-11-09 Baker Norton Pharmaceuticals, Inc. Method for treating late phase allergic reactions and inflammatory diseases
FI106923B (en) 1997-01-03 2001-05-15 Cultor Ltd Finnsugar Bioproduc Use of trimethylglycine in preparations for hygiene and care of the mucous membranes of the body
AR002194A1 (en) 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany COMPUTERIZED INSTRUMENT FOR THE ANALYSIS OF MOVEMENT.
US5981607A (en) 1998-01-20 1999-11-09 Allergan Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers
IT1302307B1 (en) 1998-09-01 2000-09-05 Sigma Tau Healthscience Spa COMPOSITION WITH ANTIOXIDANT ACTIVITY AND FOR IMPROVING THE METABOLIC USE OF GLUCOSE, INCLUDING ACETYL
US6585987B1 (en) 1998-11-13 2003-07-01 Continental Projects Limited Complexes of hyaluronic acid/carnitines and pharmaceutical and cosmetic compositions
US6228392B1 (en) 1999-04-29 2001-05-08 Gene Tools, Llc Osmotic delivery composition, solution, and method
RU2291685C2 (en) 2000-07-14 2007-01-20 Аллерган Инк. Composition containing therapeutically active ingredients having increased solubility
CA2355814C (en) 2000-09-14 2010-06-29 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Pharmaceutical composition for ophthalmic use
AU2002227206B2 (en) 2000-11-08 2006-09-21 Fxs Ventures, Llc Improved ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers
US7045121B2 (en) 2001-12-14 2006-05-16 Allergan, Inc. Ophthalmic compositions for lubricating eyes and methods for making and using same
WO2004028536A1 (en) 2002-09-30 2004-04-08 Babizhayev Mark A Method for topical treatment of eye disease and composition and device for said treatment
US20040137079A1 (en) 2003-01-08 2004-07-15 Cook James N. Contact lens and eye drop rewetter compositions and methods
US6635654B1 (en) 2003-01-09 2003-10-21 Allergan, Inc. Ophthalmic compositions containing loratadine
US20060251685A1 (en) 2003-03-18 2006-11-09 Zhi-Jian Yu Stable ophthalmic oil-in-water emulsions with Omega-3 fatty acids for alleviating dry eye
WO2004084877A1 (en) 2003-03-26 2004-10-07 Menicon Co., Ltd. Composition for ophthalmic use
CN1856251A (en) * 2003-06-11 2006-11-01 诺瓦西股份有限公司 Pharmaceutical compositions comprising active vitamin D compounds
US20050009836A1 (en) 2003-06-26 2005-01-13 Laskar Paul A. Ophthalmic composition containing quinolones and method of use
US20070265341A1 (en) 2004-07-01 2007-11-15 The Schepens Eye Research Institute Inc. Compositions and methods for treating eye disorders and conditions
CA2572344A1 (en) 2004-07-01 2006-01-19 Schepens Eye Research Compositions and methods for treating eye disorders and conditions
US8569367B2 (en) 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
US7297679B2 (en) 2005-07-13 2007-11-20 Allergan, Inc. Cyclosporin compositions
US9561178B2 (en) 2006-07-25 2017-02-07 Allergan, Inc. Cyclosporin compositions
WO2008035246A2 (en) 2006-07-28 2008-03-27 Novagali Pharma Sa Compositions containing quaternary ammonium compounds
WO2008027341A2 (en) 2006-08-30 2008-03-06 Merck & Co., Inc. Topical ophthalmic formulations
CN101668511A (en) 2007-02-28 2010-03-10 阿西克斯医疗公司 methods and compositions for normalizing meibomian gland secretions
JP4929245B2 (en) 2008-07-31 2012-05-09 株式会社ベッセル工業 Tool grip
AU2009308017A1 (en) 2008-10-20 2010-04-29 Allergan, Inc. Ophthalmic compositions useful for improving visual acuity
IT1393419B1 (en) * 2009-03-19 2012-04-20 Medivis S R L OPHTHALMIC COMPOSITIONS OF OMEGA-3 AND OMEGA-6 POLYSATURATED FATTY ACIDS.
US9480645B2 (en) * 2009-06-02 2016-11-01 Abbott Medical Optics Inc. Omega-3 oil containing ophthalmic emulsions
MX2011013007A (en) * 2009-06-05 2012-02-28 Allergan Inc Artificial tears and therapeutic uses.
US8957048B2 (en) 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
RU2014129268A (en) * 2011-12-16 2016-02-10 Аллерган, Инк. OPHTHALMIC COMPOSITIONS THAT CONTAIN GRAVITY POLYVINYL POLYVINYL PROCALT-POLYVINYL ACETATE-POLYETHYLENE Glycol copolymers
CN102934703B (en) * 2012-11-13 2015-07-15 中国食品发酵工业研究院 Flaxseed oil microcapsule and production method thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LUBRIZOL ADVANCED MATERIALS ET AL: "Introducing Pemulen polymeric Emulsifiers", 15 October 2007 (2007-10-15), pages 1 - 7, XP093045744, Retrieved from the Internet <URL:chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.lubrizol.com/-/media/Lubrizol/Health/TDS/TDS-114_Introducing_Pemulen_Polymeric_Emulsifiers.pdf> [retrieved on 20230510] *

Also Published As

Publication number Publication date
UA121399C2 (en) 2020-05-25
NZ732058A (en) 2023-06-30
AU2015353701B2 (en) 2021-03-25
CO2017005624A2 (en) 2017-10-20
AU2015353701A1 (en) 2017-06-01
KR20170086111A (en) 2017-07-25
US20160143977A1 (en) 2016-05-26
IL252161B (en) 2020-09-30
SG11201704167PA (en) 2017-06-29
CN107106483B (en) 2021-04-16
BR112017010987A2 (en) 2018-02-14
US20220143122A1 (en) 2022-05-12
CA2967413C (en) 2023-08-15
JP6768653B2 (en) 2020-10-14
RU2017117558A (en) 2018-12-26
US10279005B2 (en) 2019-05-07
CN107106483A (en) 2017-08-29
CL2017001301A1 (en) 2018-01-26
MX2017006474A (en) 2017-09-12
MX2020004076A (en) 2020-07-29
RU2697844C9 (en) 2019-10-01
CA2967413A1 (en) 2016-06-02
PH12017500922A1 (en) 2017-11-20
US20190298790A1 (en) 2019-10-03
RU2017117558A3 (en) 2019-06-05
US20240299480A1 (en) 2024-09-12
RU2697844C2 (en) 2019-08-21
JP2017535578A (en) 2017-11-30
WO2016085885A1 (en) 2016-06-02
IL252161A0 (en) 2017-07-31
KR102487299B1 (en) 2023-01-10

Similar Documents

Publication Publication Date Title
US20240299480A1 (en) Stabilized omega-3 ophthalmic compositions
US12005033B2 (en) Compositions comprising mixtures of semifluorinated alkanes
ES2965828T3 (en) Semifluorinated alkane compositions
KR101677308B1 (en) Ophthalmic compositions based on polyunsaturated omega-3 and omega-6 fatty acids
JP5663595B2 (en) Pharmaceutical composition for the treatment of dry eye syndrome
BR112014008314B1 (en) Ophthalmic composition and its use
BR112017010987B1 (en) STABILIZED OMEGA-3 OPHTHALMIC COMPOSITIONS AND THEIR USE

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20170531

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20200708

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230331